Treatment for Depression

April 24th, 2011

Excerpts from an article by John H Grohol (D. Psy)

My Introduction

I have enclosed a large segment from an article by John H Grohol (D. Psy, which I presume means psychology,) written in March 2006, on the Treatment of Depression – the whole article is available on-line and following is the link – http://psychcentral.com/disorders/sx22t.htm

John Grohol’s early version of the article (written in 1995) was one of the first pieces of literature that informed me of the methodological biases, and problems with the biological leanings in public mental health services.

What follows was new information to me about 8 years ago when I read it and I think it is still valuable reading.

The Extract

Psychotherapy, Medication or Both?

I think this question is best answered by researchers who’ve studied this issue extensively. This excerpt from an article that appeared in the American Psychological Association’s Monitor nicely summarizes the research. The preponderance of the available scientific evidence shows that psychological interventions, particularly cognitive-behavioral therapies (CBTs), are generally as effective or more effective than medications in the treatment of depression, even if severe, for both vegetative and social adjustment symptoms, especially when patient-rate measures and long-term follow-up are considered (Antonuccio, 1995 [43]).

Yale psychiatrists (Wexler & Cicchetti, 1992 [50]) conducted a meta-analysis (a large, comprehensive review of the research literature). When dropout rate is considered with treatment success rates, pharmacotherapy alone is substantially worse than psychotherapy alone or the combined treatment. The review concluded that in a hypothetical cohort of 100 patients with major depression, 29 would recover if given pharmacotherapy alone, 47 would recover if given psychotherapy alone, and 47 would recover if given combined treatment. On the other hand, negative outcome (i.e., dropout or poor response) can be expected in 52 pharmacotherapy patients, 30 psychotherapy patients, and 34 combined patients. This meta-analysis suggests that psychotherapy alone should usually be the initial treatment for depression rather than exposing patients to unnecessary costs and side effects of combined treatment (Antonuccio, 1995 [43]).

Moreover, a consistent finding across studies is a higher dropout rate among those receiving medication, either because of side effects or because the medication has not helped. These patients are treatment failures but are not included as treatment failures in the data for their studies (Karon & Teixeira, 1995 [48]).

Often times you will find doctors and researchers discussing “double-blind placebo controlled” studies as being the “gold standard” within this area of study. This simply is either ignorance or naivete. Seymour Fisher and Roger Greenberg (1993 [50]) among others, have shown the double-blind placebo controlled study is not blind. Side effects are so obvious that more than 80% of the patients know whether they are on active medication or placebo, patients are equally accurate about other patients on the ward, and nurses and other personnel are privy as well. In some studies the only people who claim to be blind are the prescribing physicians, and in other studies the prescribing physicians admit being as aware of the patients’ condition as everyone else (Karon & Teixeira, 1995 [48]).

Greenberg, Bornstein, Greenberg, and Fisher (1992 [47]) conducted another meta-analysis, covering 22 controlled studies (N=2,230). This study calls into serious question the perceived efficacy of tricyclic antidepressant medications, which are shown only to be more effective than inert placebo and only on clinician-rated measures, not patient-rated measures. If patients cannot tell that they are better off in a controlled study, one must question the conventional wisdom about the efficacy of antidepressant drugs. The newer selective serotonin reuptake inhibitors (SSRIs, such as Prozac, Paxil, and Zoloft) do not appear to fare much better (Antonuccio, 1995 [43]).

With active placebos, so that the patients and psychiatrists are not easily informed, the empirical data show that medication effect sizes are hard to distinguish from the placebo. Also not mentioned is that most antidepressant medications habituate, and the patients’ symptoms return. Most patients believe they would feel even worse if they were not taking their medication (Karon & Teixeira, 1995 [48]).

While everyone knows that it often takes years to provide evidence of safety and effectiveness and be approved by the Food and Drug Administration (FDA). But what is not known is that although these studies often have large number of participants, patients may have been given the medication for only short periods of time — much shorter periods of time than in clinical practice. Prozac, for example, has been advertised as having been administered to either 11,000 or 6,000 patients in preapproval clinical trials. But in all the controlled preapproval trials there were only a total of 286 patients on Prozac, and the controlled trials lasted only six weeks (Breggin & Breggin, 1994). In all the preapproval data submitted, 86% of the patients received Prozac for less than three months. Only 63 patients out of thousands had taken the drug for two years or more — the way it is used in clinical practice (Karon & Teixeira, 1995 [48]).

Important points that should be taken from the above excerpt:

  • Combined treatment of psychotherapy and medication is the usual and preferred treatment of choice for depression. This is likely the most commonly-used treatment for depression today and there is absolutely nothing wrong with it, since it, too, has been proven very effective. Never go against professional advice given with regards to your treatment, unless you have first discussed it with your treatment providers. Especially with depression, it is better to play it safe, than be sorry.
  • Psychotherapy is likely the second treatment of choice for depression, regardless of the depression’s severity or symptoms. Multiple meta-analyses have come to this conclusion, so it is not a conclusion based on just one lone case study or the like. (No one study, even the NIMH study on depression, should ever be used to draw far-reaching, generalized conclusions about a treatment’s effectiveness. Meta-analyses are always preferred by research scientists.)
  • Medication alone should be your last choice and only used as a last resort. Although you will likely gain some short-term relief of the most outward symptoms of your depression, the above-cited meta-analyses and multiple studies have shown that medications don’t work very well in the long-term.
  • Always consult your physician or psychiatrist before beginning or stopping any medications. This article is not meant as advice to your specific situation, but as overall education.
  • People who are taking psychotropic medications should better inform themselves as to the negative and adverse side effects of those medications. Ask your physician about these, or consult the insert for the medication (which you can also request from your doctor if you do not already have one). Also, drug handbooks found in many larger bookstores in the medical section might come in handy, as will the PDR. You might also benefit from a more thorough understanding of how political and un-scientific the drug approval process is in the United States by reading Breggin & Breggin’s book, Talking back to Prozac (1994 [45]). I don’t usually like Breggin or the positions he takes, but I found this to be a fascinating account of the FDA workings and the actual numbers used in the Prozac trials, obtained through the Freedom of Information Act. They concerned me and they should concern you too.

As Consumer Reports noted in their two articles, Pushing Drugs (Feb., 1992) and Miracle Drugs (March, 1992), physicians are actively marketed to by drug companies, given free gifts and vacations. That “professional” you think you’re paying to receive the best and most thorough treatment available may be in the pocket of a pharmaceutical company. So don’t be too surprised that when a new antidepressant medication is marketed (such as Serzone) that you suddenly see a whole host of psychiatrists prescribing it, not based upon the medical research, but because it’s new.

References

1. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER: Depression: A Neglected Major Illness. Journal of Clinical Psychiatry 1993; 54(11):419-24.
2. Elkin I, Shea MT, Watkins JT, Imber SD, Sotsky SM, Collins JF, Glass DR, Pilkonis PA, Leber WR, Docherty JP, et al: National Institute Of Mental Health Treatment Of Depression Collaborative Research Program. General Effectiveness Of Treatments. Arch Gen Psychiatry 1989; 46(11):971-82.
3. Piper A Jr: Tricyclic Antidepressants Versus Electroconvulsive Therapy: A Review Of The Evidence For Efficacy In Depression. [Review]. Annals of Clinical Psychiatry 1993; 5(1):13-23.
4. Souza FG, Goodwin GM: Lithium Treatment And Prophylaxis In Unipolar Depression: A Meta-Analysis. Br J Psychiatry 1991; 158:666-75.
5. Stuppaeck CH, Barnas C, Schwitzer J, Fleischhacker WW: Carbamazepine In The Prophylaxis Of Major Depression: A 5-Year Follow-Up. Journal of Clinical Psychiatry 1994; 55(4):146-50.
6. Hubain PP, Castro P, Mesters P, De Maertelaer V, Mendlewicz J: Alprazolam And Amitriptyline In The Treatment Of Major Depressive Disorder: A Double-Blind Clinical And Sleep EEG Study. J Affective Diss 1990; 18(1):67-73.
7. Shea MT, Elkin I, Imber SD, Sotsky SM, Watkins JT, Collins JF, Pilkonis PA, Beckham E, Glass DR, Dolan RT, et al: Course Of Depressive Symptoms Over Follow-Up. Findings From The National Institute Of Mental Health Treatment Of Depression Collaborative Research Program. Archives of General Psychiatry 1992; 49(10):782-7.
8. Kendler KS, Kessler RC, Neale MC, Heath AC, Eaves LJ: The Prediction Of Major Depression In Women: Toward An Integrated Etiologic Model. American Journal of Psychiatry 1993; 150(8):1139-48.
9. Ezquiaga E, Ayuso Gutierrez JL, Garcia Lopez A: Psychosocial Factors And Episode Number In Depression. J Affective Dis 1987; 12(2):135-8.
10. Weissman MM, Markowitz JC: Interpersonal Psychotherapy. Current Status. Archives of General Psychiatry 1994; 51(8):599-606.
11. Hollon SD, Shelton RC, Davis DD: Cognitive Therapy For Depression: Conceptual Issues And Clinical Efficacy. Journal of Consulting & Clinical Psychology 1993; 61(2):270-5. [REVIEW]
12. Watkins JT, Leber WR, Imber SD, Collins JF, Elkin I, Pilkonis PA, Sotsky SM, Shea MT, Glass DR: Temporal Course Of Change Of Depression. Journal of Consulting & Clinical Psychology 1993; 61(5):858-64.
13. Fava M, Bless E, Otto MW, Pava JA, Rosenbaum JF: Dysfunctional Attitudes In Major Depression. Changes With Pharmacotherapy. Journal of Nervous & Mental Disease 1994; 182(1):45-9.
14. Svartberg M, Stiles TC: Comparative Effects Of Short-Term Psychodynamic Psychotherapy: A Meta-Analysis. Journal of Consulting & Clinical Psychology 1991; 59(5):704-14.
15. Beardslee WR, Hoke L, Wheelock I, Rothberg PC, van de Velde P, Swatling S: Initial Findings On Preventive Intervention For Families With Parental Affective Disorders. American Journal of Psychiatry 1992; 149(10):1335-40.
16. Stokes PE: Current Issues In The Treatment Of Major Depression. [Review]. Journal of Clinical Psychopharmacology 1993; 13(6 Suppl 2):2S-9S.
17. Rutz W, von Knorring L, Walinder J: Long-term Effects of an Educational Program For General Practitioners Given By The Swedish Committee For The Prevention And Treatment Of Depression. Acta Psychiatrica Scandinavica 1992; 85(1):83-8.
18. Isacsson G, Boethius G, Bergman U: Low Level Of Antidepressant Prescription For People Who Later Commit Suicide: 15 Years Of Experience From A Population-Based Drug Database In Sweden. Acta Psychiatrica Scandinavica 1992; 85(6):444-8.
19. Isometsa ET, Henriksson MM, Aro HM, Heikkinen ME, Kuoppasalmi KI, Lonnqvist JK: Suicide In Major Depression. American Journal of Psychiatry 1994; 151(4):530-6.
20. Simon GE, VonKorff M, Wagner EH, Barlow W: Patterns Of Antidepressant Use In Community Practice. General Hospital Psychiatry 1993; 15(6):399-408.
21. Kapur S, Mieczkowski T, Mann JJ: Antidepressant Medications And The Relative Risk Of Suicide Attempt And Suicide .. JAMA 1992; 268(24):3441-5.
22. Nemeroff CB: Evolutionary Trends In The Pharmacotherapeutic Management Of Depression. [Review]. Journal of Clinical Psychiatry 1994; 55 Suppl:3-15; discussion 16-7.
23. Piccinelli M, Wilkinson G: Outcome Of Depression In Psychiatric Settings. [Review]. British Journal of Psychiatry 1994; 164(3):297-304.
24. Greden JF: Antidepressant Maintenance Medications: When To Discontinue And How To Stop. [Review]. Journal of Clinical Psychiatry 1993; 54 Suppl:39-45; discussion 46-7.
25. Lonnqvist J, Sintonen H, Syvalahti E, Appelberg B, Koskinen T, Mannikko T, Mehtonen OP, Naarala M, Sihvo S, Auvinen J, et al: Antidepressant Efficacy And Quality Of Life In Depression: A Double-Blind Study With Moclobemide And Fluoxetine. Acta Psychiatrica Scandinavica 1994; 89(6):363-9.
26. Peet M: Induction Of Mania With Selective Serotonin Re-Uptake Inhibitors And Tricyclic Antidepressants. British Journal of Psychiatry 1994; 164(4):549-50.
27. Tignol J: A Double-Blind, Randomized, Fluoxetine-Controlled, Multicenter Study Of Paroxetine In The Treatment Of Depression. Journal of Clinical Psychopharmacology 1993; 13(6 Suppl 2):18S-22S.
28. Stokes PE: Fluoxetine: A Five-Year Review. [Review]. Clinical Therapeutics 1993; 15(2):216-43; discussion 215.
29. Nemeroff CB: Paroxetine: An Overview Of The Efficacy And Safety Of A New Selective Serotonin Reuptake Inhibitor In The Treatment Of Depression. [Review]. Journal of Clinical Psychopharmacology 1993; 13(6 Suppl 2):10S-17S.
30. Kishimoto A, Kamata K, Sugihara T, Ishiguro S, Hazama H, Mizukawa R, Kunimoto N: Treatment Of Depression With Clonazepam. Acta Psychiatr Scand 1988; 77(1):81-6.
31. Fava M, Rosenbaum JF, McGrath PJ, Stewart JW, Amsterdam JD, Quitkin FM: Lithium And Tricyclic Augmentation Of Fluoxetine Treatment For Resistant Major Depression: A Double-Blind, Controlled Study. American Journal of Psychiatry 1994; 151(9):1372-4.
32. Brown WA, Harrison W: Are Patients Who Are Intolerant To One Serotonin Selective Reuptake Inhibitor Intolerant To Another?. Journal of Clinical Psychiatry 1995; 56(1):30-4.
33. Delgado PL, Price LH, Charney DS, Heninger GR: Efficacy Of Fluvoxamine In Treatment-Refractory Depression. J Affective Dis 1988; 15(1):55-60.
34. Feighner JP: The Role Of Venlafaxine In Rational Antidepressant Therapy. [Review]. Journal of Clinical Psychiatry 1994; 55 Suppl A:62-8; discussion 69-70, 98-100.
35. Joffe RT, Singer W, Levitt AJ, MacDonald C: A Placebo-Controlled Comparison Of Lithium And Triiodothyronine Augmentation Of Tricyclic Antidepressants In Unipolar Refractory Depression. Archives of General Psychiatry 1993; 50(5):387-93.
36. Howland RH: Thyroid Dysfunction In Refractory Depression: Implications For Pathophysiology And Treatment. [Review]. Journal of Clinical Psychiatry 1993; 54(2):47-54.
37. Nelson JC, Mazure CM, Bowers MB Jr, Jatlow PI: A Preliminary, Open Study Of The Combination Of Fluoxetine And Desipramine For Rapid Treatment Of Major Depression. Arch Gen Psychiatry 1991; 48(4):303-7.
38. Schaff MR, Fawcett J, Zajecka JM: Divalproex Sodium In The Treatment Of Refractory Affective Disorders. Journal of Clinical Psychiatry 1993; 54(10):380-4.
39. Warneke L: Psychostimulants In Psychiatry. Can J Psychiatry 1990; 35(1):3-10.
40. Partonen T, Partinen M: Light Treatment For Seasonal Affective Disorder: Theoretical Considerations And Clinical Implications. [Review]. Acta Psychiatrica Scandinavica, Supplementum 1994; 377:41-5.
41. Rothschild AJ, Samson JA, Bessette MP, Carter-Campbell JT: Efficacy Of The Combination Of Fluoxetine And Perphenazine In The Treatment Of Psychotic Depression. Journal of Clinical Psychiatry 1993; 54(9):338-42.
42. el-Mallakh RS: Complications Of Concurrent Lithium And Electroconvulsive Therapy: A Review Of Clinical Material And Theoretical Considerations. Biol Psychiatry 1988; 23(6):595-601.
43. Antonuccio, D.O. (1995). Psychotherapy for depression: No stronger medicine. American Psychologist, 50, 450-452.
44. Antonuccio, D.O., Danton, W.G., & DeNelsky, G.Y. (1994). Psychotherapy for depression: No stronger medicine. Scientist Practitioner, 4(1), 2-18.
45. Breggin, P.R., & Breggin, G.R. (1994). Talking back to Prozac. New York: St. Martin’s Press.
46. Fisher, S., & Greenberg, R.P. (1993). How sounds is the double-blind design for evaluating psychotropic drugs? The Journal of Nervous and Mental Disease, 181, 345-350.
47. Greenberg, R.P., Bornstein, R.F., Greenberg, M.D., & Fisher, S. (1992). A meta-analysis of antidepressant outcome under “blinder” conditions. Journal of Consulting and Clinical Psychology, 60, 664-669.
48. Karon, B.P., & Teixeira, M.A. (1995). “Guidelines for the treatment of depression in primary care” and the APA response. American Psychologist, 50, 453-455.
49. Munoz, R.F., Hollon, S.D., McGrath, E., Rehm, L.P., & VanderBos, G.R. (1994). On the AHCPR depression in primary care guidelines: Further considerations for practitioners. American Psychologist, 49, 42-61.
50. Wexler, B.E., & Cicchetti, D.V. (1992). The outpatient treatment of depression: Implications of outcome research for clinical practice. The Journal of Nervous and Mental Disease, 180(5), 277-286.

(The End.)


Trackback URI | Comments RSS

Leave a Reply

Name (required)

Email (required)

Website

Speak your mind